Immunotherapy company ImmunityBio has partnered with Microsoft to leverage the latter’s Azure platform to create a 3D model of Covid-19’s spike protein.
The novel coronavirus’ spike protein allows the virus to dock and bind to the ACE2 surface protein of human epithelial cells in the respiratory tract, thereby infecting these cells so they reproduce thousands of copies of the virus.
Having a clear understanding of this high-profile target will support and accelerate the development of antibody therapies and vaccines against Covid-19.
ImmunityBio and Microsoft’s model leveraged a digital blueprint of Covid-19’s spike protein published by the US National Institute of Health and University of Texas in early March.